Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 75,311 shares, a decrease of 32.7% from the February 12th total of 111,873 shares. Based on an average daily trading volume, of 54,415 shares, the short-interest ratio is currently 1.4 days. Approximately 4.6% of the company’s stock are short sold. Approximately 4.6% of the company’s stock are short sold. Based on an average daily trading volume, of 54,415 shares, the short-interest ratio is currently 1.4 days.

Catheter Precision Trading Down 7.1%

Catheter Precision stock traded down $0.11 during trading hours on Friday, reaching $1.37. 141,223 shares of the company were exchanged, compared to its average volume of 1,348,230. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. Catheter Precision has a 12 month low of $1.14 and a 12 month high of $15.68. The stock has a 50-day moving average of $1.82 and a 200 day moving average of $2.17.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.